Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs KeyCorp (KEY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs KeyCorp — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $223.05 (market cap $29.60B), while KeyCorp trades at $22.82 (market cap $24.32B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and KeyCorp pays a 3.61% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | KEY | |
|---|---|---|
Market Cap | $29.60B | $24.32B |
Sector | Health | Financials |
52-Week High | $491.22 | $23.99 |
52-Week Low | $205.48 | $16.78 |
Enterprise Value | $27.56B | — |
Dividend Yield | — | 3.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.
The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.
KeyCorp (KEY) trades at $22.855, up 0.77% for the day, with a P/E of 13.27 and P/B of 1.41. Recent quarterly earnings have consistently beaten estimates, with Q2 2026 EPS of $0.44 versus $0.42 expected. Technical indicators show a bearish trend, but fundamentals are supported by strong net interest income growth and strategic acquisitions like Clearwater UK.
The outlook is positive with a consensus price target of $29.41, implying 29% upside. Risks include economic uncertainty impacting loan growth and margin pressure from rising expenses. Analyst sentiment is bullish with 61% buy ratings, but investors should monitor execution of fee-based growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About KeyCorp
With assets of over $170 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
Read more on KEY →
